Clinical Trial Update: Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial assessing safety, tolerability, and immunogenicity of Novartis' recombinant meningococcal B vaccine in healthy adolescents unde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal B Recombinant Vaccine (Meningococcal B recombinant vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-11-04